Dr. Burgin is the senior director of the Center for the Development of Therapeutics at the Broad Institute of MIT and Harvard, where he leads the center on an innovative and purpose-driven path to discover new therapeutics with important clinical impact.
A scientist by training, Dr. Burgin has over 30 years’ experience spanning both academia and the private sector. He completed his postdoctoral training at the National Institutes of Health, and was enzymology group leader at Ribozyme Pharmaceuticals prior to joining the faculty of San Diego State University, where he ran an active research and training program. He then joined Emerald BioStructures where, as chief operating officer and then as chief scientific officer, he led multiple drug discovery projects. After leaving industry, he served as the senior scientific advisor to the Broad’s chief scientific officer, and then served as executive director at the Institute for Protein Innovation before returning to the Broad as a senior director.
Dr. Burgin holds an A.B. from Wabash College and a Ph.D. in genetics from Indiana University.